Publication:
Kidney loss due to periureteral fibrosis and ureteral obstruction secondary to migration of subureterically injected calcium hydroxylapatite

dc.contributor.authorsÖnol F.F., Tarcan T., Tinay I., Kotiloǧlu E., Şimşek F.
dc.date.accessioned2022-03-15T01:55:18Z
dc.date.accessioned2026-01-11T09:06:19Z
dc.date.available2022-03-15T01:55:18Z
dc.date.issued2006
dc.description.abstractVesicoureteral reflux (VUR) is one of the significant urologic diseases of childhood and its endoscopic treatment is a viable option in terms of both simplicity and reduced morbidity. However, despite intensive research, no ideal injection material that yields the best long-term results with the least side effects has been introduced as yet. Synthetic calcium hydroxylapatite is one of the materials that has recently been under trial. Although favorable short-term success rates have been reported with the subureteric injection of calcium hydroxylapatite without any side effects, this case report shows its potential to migrate. To our knowledge, we present the first case where the migration of subureterically injected calcium hydroxylapatite resulted in periureteral fibrosis, ureteric obstruction and subsequent renal loss. © 2005 Journal of Pediatric Urology Company.
dc.identifier.doi10.1016/j.jpurol.2005.10.006
dc.identifier.issn14775131
dc.identifier.urihttps://hdl.handle.net/11424/246708
dc.language.isoeng
dc.relation.ispartofJournal of Pediatric Urology
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectInjection
dc.subjectMigration
dc.subjectTreatment
dc.subjectVesicoureteral reflux
dc.titleKidney loss due to periureteral fibrosis and ureteral obstruction secondary to migration of subureterically injected calcium hydroxylapatite
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage508
oaire.citation.issue5
oaire.citation.startPage503
oaire.citation.titleJournal of Pediatric Urology
oaire.citation.volume2

Files